[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1115808T1 - Ενδιαμεσα για την παρασκευη δισθενων μιμητικων toυ smac - Google Patents

Ενδιαμεσα για την παρασκευη δισθενων μιμητικων toυ smac

Info

Publication number
CY1115808T1
CY1115808T1 CY20141101018T CY141101018T CY1115808T1 CY 1115808 T1 CY1115808 T1 CY 1115808T1 CY 20141101018 T CY20141101018 T CY 20141101018T CY 141101018 T CY141101018 T CY 141101018T CY 1115808 T1 CY1115808 T1 CY 1115808T1
Authority
CY
Cyprus
Prior art keywords
smac
smacle
divisions
preparation
relates
Prior art date
Application number
CY20141101018T
Other languages
English (en)
Inventor
Shaomeng Wang
Haiying Sun
Dongguang Qin
Zaneta Nikolovska-Coleska
Su Qiu
Yuefeng Peng
Qian Cai
Original Assignee
The Regents Of The University Of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of Michigan filed Critical The Regents Of The University Of Michigan
Publication of CY1115808T1 publication Critical patent/CY1115808T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Η εφεύρεση αφορά σε δισθενή μιμητικά του Smac που λειτουργούν ως αναστολείς του Αναστολέα Πρωτεϊνών Απόπτωσης. Η εφεύρεση επίσης αφορά στη χρήση αυτών των μιμητικών για διέγερση αποπτωτικού θανάτου κυττάρου και για ευαισθητοποίηση κυττάρων σε διεγέρτες απόπτωσης.
CY20141101018T 2006-05-05 2014-12-08 Ενδιαμεσα για την παρασκευη δισθενων μιμητικων toυ smac CY1115808T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79801806P 2006-05-05 2006-05-05
US92341507P 2007-04-13 2007-04-13
EP07794581.4A EP2019671B1 (en) 2006-05-05 2007-05-04 Intermediates for the preparation of bivalent smac mimetics

Publications (1)

Publication Number Publication Date
CY1115808T1 true CY1115808T1 (el) 2017-01-25

Family

ID=38668354

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141101018T CY1115808T1 (el) 2006-05-05 2014-12-08 Ενδιαμεσα για την παρασκευη δισθενων μιμητικων toυ smac

Country Status (23)

Country Link
US (1) US7960372B2 (el)
EP (1) EP2019671B1 (el)
JP (1) JP5230610B2 (el)
KR (1) KR101071516B1 (el)
CN (1) CN101484151B (el)
AU (1) AU2007248473B2 (el)
BR (1) BRPI0711326B8 (el)
CA (1) CA2651206C (el)
CY (1) CY1115808T1 (el)
DK (1) DK2019671T3 (el)
EA (1) EA017279B1 (el)
ES (1) ES2525585T3 (el)
HK (1) HK1124536A1 (el)
HR (1) HRP20141253T1 (el)
IL (1) IL195075A (el)
MX (1) MX2008014140A (el)
NO (1) NO341896B1 (el)
NZ (1) NZ572531A (el)
PL (1) PL2019671T3 (el)
PT (1) PT2019671E (el)
SI (1) SI2019671T1 (el)
WO (1) WO2007130626A2 (el)
ZA (1) ZA200809496B (el)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5230865B2 (ja) 2004-07-15 2013-07-10 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ結合性化合物
DK1851200T3 (da) 2005-02-25 2014-04-14 Tetralogic Pharm Corp Dimere iap-inhibitorer
WO2006122408A1 (en) * 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
BRPI0617751A2 (pt) 2005-10-25 2011-08-02 Aegera Therapeutics Inc compostos de ligação do domìnio iap bir
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
KR101506466B1 (ko) 2006-05-16 2015-03-27 파마사이언스 인크. Ｉａｐ ｂｉｒ 도메인 결합 화합물
AR064235A1 (es) * 2006-07-24 2009-03-25 Tetralogic Pharmaceuticals Cor Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer
WO2008014263A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap antagonists
US20100143499A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014240A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014229A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
KR101081685B1 (ko) * 2007-04-13 2011-11-09 더 리젠츠 오브 더 유니버시티 오브 미시간 디아조 바이사이클릭 ｓｍａｃ 모사체 및 그의 용도
CA2686638A1 (en) * 2007-05-07 2008-11-13 Tetralogic Pharmaceuticals Corp. Tnf.alpha. gene expression as a biomarker of sensitivity to antagonists of inhibitor of apoptosis proteins
WO2008144925A1 (en) * 2007-05-30 2008-12-04 Aegera Therapeutics Inc. Iap bir domain binding compounds
CA2725398A1 (en) * 2008-04-11 2009-10-15 The Regents Of The University Of Michigan Heteroaryl-substituted bicyclic smac mimetics and the uses thereof
WO2009136290A1 (en) * 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
EP2310402A1 (en) * 2008-06-27 2011-04-20 Aegera Therapeutics Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
CN102123763B (zh) 2008-08-19 2014-10-08 什诺波特有限公司 富马酸氢甲酯的前体药物、其药物组合物、及其使用方法
WO2010033315A1 (en) * 2008-09-22 2010-03-25 Amgen Inc. Method of treatment
US20110319362A1 (en) * 2008-12-08 2011-12-29 Shaomeng Wang Stat3 ligands and therapeutic uses thereof
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
WO2011050068A2 (en) * 2009-10-23 2011-04-28 The Regents Of The University Of Michigan Bivalent diazo bicyclic smac mimetics and the uses thereof
AU2011214057B2 (en) 2010-02-12 2016-11-17 Pharmascience Inc. IAP BIR domain binding compounds
JP2012126649A (ja) * 2010-12-13 2012-07-05 Satoshi Anai 膀胱癌増殖抑制用組成物
GB201106817D0 (en) * 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
CN104169261A (zh) 2012-02-07 2014-11-26 什诺波特有限公司 富马酸吗啉代烃基酯化合物、药物组合物和使用方法
EP2887935A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
EP2888265B1 (en) * 2012-08-23 2017-10-11 The Regents of The University of Michigan Bivalent inhibitors of iap proteins and therapeutic methods using the same
JP5964727B2 (ja) * 2012-11-05 2016-08-03 高砂香料工業株式会社 α―フムラジエノンの製造方法
DK2970101T3 (en) 2013-03-14 2018-08-20 Alkermes Pharma Ireland Ltd PRO-DRUGS OF FUMARATES AND THEIR USE IN TREATING DIFFERENT DISEASES
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
EP3682873B1 (en) * 2013-06-25 2024-06-12 The Walter and Eliza Hall Institute of Medical Research Smac mimetics for use in the treatment of persistent hiv infection
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
TW201516020A (zh) 2013-09-06 2015-05-01 Xenoport Inc （ｎ，ｎ－二乙基胺甲醯基）甲基（２ｅ）丁－２－烯－１，４－二酸甲酯之晶形、合成方法及用途
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2015187998A2 (en) 2014-06-04 2015-12-10 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
WO2016061393A1 (en) 2014-10-15 2016-04-21 Xenoport, Inc. Fumarate compounds, pharmaceutical compositions, and methods of use
WO2016118666A1 (en) 2015-01-20 2016-07-28 Arvinas, Inc. Compounds and methods for the targeted degradation of the androgen receptor
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
JP2018503651A (ja) 2015-02-08 2018-02-08 アルカーメス ファーマ アイルランド リミテッド フマル酸モノメチルプロドラッグ組成物
WO2016160635A1 (en) 2015-03-27 2016-10-06 Sytheon Limited Compositions and methods for treating psoriasis
EP3302482A4 (en) 2015-06-05 2018-12-19 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
WO2017060400A1 (en) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
AU2017367872B2 (en) 2016-11-01 2022-03-31 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
EP3559002A4 (en) 2016-12-23 2021-02-17 Arvinas Operations, Inc. CHEMERICAL MOLECULES TARGETING EGFR PROTEOLYSIS AND RELATED METHODS OF USE
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
CN110741004B (zh) 2016-12-23 2023-10-17 阿尔维纳斯运营股份有限公司 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
CN110198924A (zh) * 2017-01-18 2019-09-03 三菱瓦斯化学株式会社 化合物、树脂、组合物和图案形成方法
KR20230140606A (ko) 2017-01-26 2023-10-06 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 단백질 분해 조절제 및 관련 사용 방법
WO2019099926A1 (en) 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
CN107987083A (zh) 2017-11-24 2018-05-04 江苏亚盛医药开发有限公司 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物
AU2019249231B2 (en) 2018-04-04 2022-04-21 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
CN108484640B (zh) * 2018-05-22 2020-09-15 南京华威医药科技集团有限公司 一种抗肿瘤的细胞凋亡蛋白抑制剂
US11707452B2 (en) 2018-08-20 2023-07-25 Arvinas Operations, Inc. Modulators of alpha-synuclein proteolysis and associated methods of use
WO2020109328A1 (en) 2018-11-26 2020-06-04 Debiopharm International S.A. Combination treatment of hiv infections
MX2021006156A (es) * 2018-11-30 2021-09-08 Glaxosmithkline Ip Dev Ltd Compuestos utiles en la terapia para el vih.
US10870663B2 (en) 2018-11-30 2020-12-22 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
US10918624B2 (en) * 2019-06-03 2021-02-16 Imam Abdulrahman Bin Faisal University Anti-cancer azole compounds
EP3999182A1 (en) 2019-07-17 2022-05-25 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
CN118986983A (zh) 2019-08-26 2024-11-22 阿尔维纳斯运营股份有限公司 用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法
AU2020356356A1 (en) 2019-09-25 2022-05-12 Debiopharm International S.A. Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma
CA3166980A1 (en) 2020-01-20 2021-07-29 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
JP2023539663A (ja) 2020-08-28 2023-09-15 アルビナス・オペレーションズ・インコーポレイテッド 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法
BR112023004656A2 (pt) 2020-09-14 2023-05-09 Arvinas Operations Inc Formas cristalinas e amorfas de um composto para a degradação direcionada do receptor de estrogênio
CN117304253A (zh) * 2022-06-22 2023-12-29 中国药科大学 一种二氮杂双环拟肽衍生物的制备方法及应用
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US4415496A (en) * 1981-03-23 1983-11-15 Merck & Co., Inc. Bicyclic lactams
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5141648A (en) 1987-12-02 1992-08-25 Neorx Corporation Methods for isolating compounds using cleavable linker bound matrices
US5165923A (en) 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
US5262524A (en) 1990-03-09 1993-11-16 Hybritech Incorporated Method for the synthesis of trifunctional maleimide-antibody complex
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
US5212075A (en) 1991-04-15 1993-05-18 The Regents Of The University Of California Compositions and methods for introducing effectors to pathogens and cells
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
US5856571A (en) 1995-06-07 1999-01-05 Cellpro, Incorporated Semicarbazide-containing linker compounds for formation of stably-linked conjugates and methods related thereto
DE69626849T2 (de) 1995-12-22 2003-12-24 Bristol-Myers Squibb Co., Princeton Verzweigte hydrazongruppen enthaltende kuppler
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
GB9724143D0 (en) 1997-11-14 1998-01-14 Andaris Ltd Pharmaceutical conjugate
US6521431B1 (en) 1999-06-22 2003-02-18 Access Pharmaceuticals, Inc. Biodegradable cross-linkers having a polyacid connected to reactive groups for cross-linking polymer filaments
AU5811001A (en) * 2000-05-09 2001-11-20 Univ British Columbia Cxcr4 antagonist treatment of hematopoietic cells
ATE206211T1 (de) 2000-05-16 2001-10-15 Biochip Technologies Gmbh Linker-system zum aktivieren von oberflächen für die biokonjugation und verfahren zu ihrer verwendung
US6992063B2 (en) * 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
EP1355672A2 (en) 2000-12-01 2003-10-29 Cell Works Inc. Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use
US7041696B2 (en) * 2002-06-17 2006-05-09 The Procter & Gamble Company Interleukin-1β converting enzyme inhibitors
EP1715882A4 (en) 2004-01-16 2009-04-08 Univ Michigan SMAC-PEPTIDOMIMETIKA AND ITS USES
JP2007522116A (ja) * 2004-01-16 2007-08-09 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン コンホメーションが制約されたＳｍａｃ模倣物およびその使用
US6887952B1 (en) 2004-02-12 2005-05-03 Biosite, Inc. N-aryl-carbamic acid ester-derived and valeric acid ester-derived cross-linkers and conjugates, and methods for their synthesis and use
WO2005084317A2 (en) * 2004-03-01 2005-09-15 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
JP5122275B2 (ja) * 2004-03-23 2013-01-16 ジェネンテック， インコーポレイテッド Ｉａｐのアザビシクロ−オクタンインヒビター
WO2006010118A2 (en) * 2004-07-09 2006-01-26 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
EA200700225A1 (ru) * 2004-07-12 2008-02-28 Айдан Фармасьютикалз, Инк. Аналоги тетрапептида
AR064235A1 (es) 2006-07-24 2009-03-25 Tetralogic Pharmaceuticals Cor Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer
WO2008014263A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap antagonists

Also Published As

Publication number Publication date
IL195075A (en) 2015-03-31
ZA200809496B (en) 2010-02-24
BRPI0711326B1 (pt) 2020-12-01
US20080089896A1 (en) 2008-04-17
JP2009536204A (ja) 2009-10-08
CN101484151A (zh) 2009-07-15
CA2651206A1 (en) 2007-11-15
NZ572531A (en) 2011-09-30
KR20090009307A (ko) 2009-01-22
IL195075A0 (en) 2009-08-03
WO2007130626A2 (en) 2007-11-15
BRPI0711326A2 (pt) 2011-08-30
KR101071516B1 (ko) 2011-10-10
CN101484151B (zh) 2012-11-21
PL2019671T3 (pl) 2015-02-27
EP2019671B1 (en) 2014-09-24
EA200802285A1 (ru) 2009-08-28
EP2019671A4 (en) 2010-06-02
HRP20141253T1 (en) 2015-03-13
NO341896B1 (no) 2018-02-12
WO2007130626A3 (en) 2008-01-17
MX2008014140A (es) 2009-01-19
PT2019671E (pt) 2014-12-18
HK1124536A1 (en) 2009-07-17
ES2525585T3 (es) 2014-12-26
BRPI0711326B8 (pt) 2021-05-25
CA2651206C (en) 2013-11-12
JP5230610B2 (ja) 2013-07-10
EP2019671A2 (en) 2009-02-04
DK2019671T3 (en) 2014-12-08
AU2007248473A1 (en) 2007-11-15
NO20085074L (no) 2009-02-04
US7960372B2 (en) 2011-06-14
SI2019671T1 (sl) 2015-03-31
EA017279B1 (ru) 2012-11-30
AU2007248473B2 (en) 2011-01-27

Similar Documents

Publication Publication Date Title
CY1115808T1 (el) Ενδιαμεσα για την παρασκευη δισθενων μιμητικων toυ smac
EA200901400A1 (ru) Бициклические диазомиметики smac и их применения
CY1117833T1 (el) Νεες συνθεσεις και μεθοδοι για την αγωγη του καρκινου
CY1123552T1 (el) Θεραπειες συνδυασμου με χρηση μοριων προσδεσης psl και pcrv αντι- pseudomonas
CY1116064T1 (el) Συστασεις αναστολεα ddp iv
CY1116435T1 (el) Ενωσεις βορονικου εστερα και φαρμακευτικες συνθεσεις αυτων
CY1116578T1 (el) Αναστολεις της bromodomain και χρησεις αυτων
CY1117942T1 (el) Αντισωματα προσδεματος επαγωγης πολλαπλασιασμου (april)
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
EA200870185A1 (ru) Комбинации ингибиторов ang2 и vegf
CR11107A (es) INDOLES SUSTITUIDOS EN LA POSICION 7 INHIBIDORES DE Mcl-1
EA200900360A1 (ru) Новые низкомолекулярные ингибиторы mdm2 и их применение
ECSP11011297A (es) Proteinas ligadoras il-17
EA200601562A1 (ru) Сокристаллы госсипола и их применение
WO2005069894A3 (en) Conformationally constrained smac mimetics and the uses thereof
WO2006010118A3 (en) Conformationally constrained smac mimetics and the uses thereof
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
UY29853A1 (es) Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas-
CR20110066A (es) Anticuerpos monoclonales contra el factor tisular inhibidor de la via
WO2005069888A3 (en) Smac peptidomimetics and the uses thereof
ECSP10010344A (es) Azolilmetiloxiranos, su uso y agentes que los contienen
DOP2006000226A (es) Derivados de carbamoilbenzotriazol como inhibidores de lipasas fosfolipasas
MX337059B (es) Metodos y composiciones para modular la hemostasia.
CY1118710T1 (el) Συνθεσεις για την θεραπεια της πολλαπλης σκληρυνσης